10% Off
Myleran2 mg
Technokit Healthcare Ltd
৳9.27
Out Of Stock
Generic medicine
Busulfan: Brands, Price & Uses in Bangladesh
Busulfan is a cytotoxic alkylating agent used only under the direction of a specialized hematology-oncology/transplant team.
About Busulfan
Indications of Busulfan
Busulfan is a cytotoxic alkylating agent used only under the direction of a specialized hematology-oncology/transplant team. Its indications are classified below by strength of evidence.
Established / FDA-approved uses
- Conditioning regimen before allogeneic hematopoietic stem cell transplantation (HSCT): Intravenous Busulfan, in combination with cyclophosphamide, is indicated as part of a preparative (conditioning) regimen prior to allogeneic HSCT for chronic myelogenous leukemia (CML).
- Chronic myelogenous leukemia (CML), palliative treatment: Oral Busulfan is indicated for the palliative treatment of CML, historically used to reduce white blood cell counts and induce hematologic remission.
Guideline-supported / adjunct transplant use (requires combination therapy)
- Busulfan-containing conditioning regimens (e.g., combined with cyclophosphamide or fludarabine) are used per institutional transplant protocols as conditioning for HSCT in other hematologic malignancies (such as acute myeloid leukemia and myelodysplastic syndrome) and in select non-malignant conditions requiring stem cell transplantation. This broader conditioning use is standard practice in transplant centers though it extends beyond the narrowest label wording, and must always be directed by a specialized transplant physician.
Historical / largely superseded use
- As monotherapy for long-term CML control, oral Busulfan has been largely replaced by tyrosine kinase inhibitors (e.g., imatinib), which are now first-line; Busulfan is reserved for specific transplant-conditioning or select second-line scenarios.
Dosage & Administration of Busulfan
Conditioning for allogeneic stem cell transplantation (intravenous)
| Population | Typical regimen |
|---|---|
| Adults and adolescents | A weight-based or body-surface-area-based dose of intravenous Busulfan is given every 6 hours (or, per some protocols, once daily) over 4 consecutive days, in combination with cyclophosphamide, immediately before stem cell infusion. Dosing is individualized, and many centers use therapeutic drug monitoring (pharmacokinetic sampling) to target a specific area-under-the-curve exposure and adjust subsequent doses. |
| Children | Dosing is calculated on a weight or body-surface-area basis and is more variable than in adults; therapeutic drug monitoring is strongly recommended to individualize dosing. See Pediatric Uses. |
| Renal/hepatic impairment | Used with caution and closer monitoring; formal dose-adjustment guidelines are not well established, so treating centers individualize based on clinical status and, where available, drug-level monitoring. |
Chronic myelogenous leukemia (oral)
| Population | Typical regimen |
|---|---|
| Adults | An initial daily oral dose (calculated on a weight or body-surface-area basis) is given until the white blood cell count falls to a target level, after which the dose is reduced or the drug is discontinued; blood counts are monitored closely and treatment is individualized by the treating hematologist. |
| Children | CML is rare in children; when used, dosing is calculated on a weight or body-surface-area basis under specialist supervision. |
Seizure-prophylaxis (an anticonvulsant, commonly phenytoin) is standard practice during high-dose intravenous conditioning because of an increased seizure risk with Busulfan (see Precautions and Warnings). Busulfan must only be prescribed and administered by, or under the direction of, a specialized hematology-oncology/transplant physician.
Side Effects of Busulfan
Profound and prolonged bone marrow suppression is an expected, dose-related effect of Busulfan (and the intended effect in transplant conditioning) rather than an unpredictable adverse reaction; other effects include:
- Very common: Neutropenia, thrombocytopenia, anemia (myelosuppression); nausea, vomiting, mucositis/stomatitis, diarrhea, anorexia.
- Common: Skin hyperpigmentation, alopecia, fatigue, fever, headache, insomnia, elevated liver enzymes.
- Serious/less common: Hepatic veno-occlusive disease (sinusoidal obstruction syndrome), seizures, interstitial pulmonary fibrosis ("busulfan lung"), cataracts with long-term use, gonadal suppression/infertility and amenorrhea, secondary malignancies in long-term survivors, engraftment syndrome.
See Precautions and Warnings for detail on the serious risks above.
Contraindications of Busulfan
Busulfan is contraindicated in patients with known hypersensitivity to Busulfan or any component of the formulation, and in pregnancy, given its cytotoxic and teratogenic potential (see Pregnancy and Lactation).
Frequently Asked Questions about Busulfan
What is Busulfan used for?
Busulfan is a chemotherapy (alkylating) agent used mainly as part of high-dose conditioning regimens before stem cell transplantation, and, historically, for the palliative treatment of chronic myelogenous leukemia. It is only given in a specialized hospital or transplant unit.
Why does Busulfan cause such severe blood count drops?
Severe, profound bone marrow suppression is an expected effect of Busulfan, and in the transplant-conditioning setting it is actually the intended goal - it clears the recipient's marrow so that donor stem cells can engraft. Close monitoring and specialized supportive care (transfusions, infection prevention, growth factors) are provided throughout.
Can Busulfan be used during pregnancy?
No. Busulfan is contraindicated in pregnancy because it is cytotoxic and can harm a developing fetus. Effective contraception is required during treatment, and pregnancy should be ruled out beforehand; discuss any pregnancy plans with your treating physician.
Why do I need anti-seizure medicine while receiving Busulfan?
Seizures have been reported with Busulfan, especially during high-dose conditioning regimens. Because of this, doctors routinely give a preventive anticonvulsant, such as phenytoin, alongside high-dose Busulfan to reduce this risk.
What is veno-occlusive disease, and why does my care team watch for it during Busulfan treatment?
Hepatic veno-occlusive disease (also called sinusoidal obstruction syndrome) is a serious, potentially fatal liver complication linked particularly to high-dose intravenous Busulfan. Your team will keep you well hydrated and watch closely for warning signs such as rapid weight gain, yellowing of the skin/eyes, pain under the right ribs, and abdominal swelling, so it can be caught and treated early.
What should be done if too much Busulfan is given or taken?
An overdose of Busulfan is a medical emergency. There is no specific antidote, so immediate medical attention is essential; treatment focuses on supportive care for bone marrow and organ toxicity, and hemodialysis has been used in some cases of significant overexposure. Contact emergency services or poison control right away.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.